The Discounted Cash Flow (DCF) valuation of Ultragenyx Pharmaceutical Inc (RARE) is (298.95) USD. With the latest stock price at 39.91 USD, the upside of Ultragenyx Pharmaceutical Inc based on DCF is -849.1%.
Based on the latest price of 39.91 USD and our DCF valuation, Ultragenyx Pharmaceutical Inc (RARE) is a sell. selling RARE stocks now will result in a potential gain of 849.1%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.5% - 8.4% | 7.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (682.44) - (195.46) | (298.95) |
| Upside | -1810.0% - -589.7% | -849.1% |